|Bid||123.0900 x 800|
|Ask||123.1300 x 800|
|Day's range||121.6800 - 123.3750|
|52-week range||118.6200 - 148.3200|
|PE ratio (TTM)||272.58|
|Earnings date||17 Jul 2018|
|Forward dividend & yield||3.60 (2.94%)|
|1y target est||144.45|
In a volatile year for the U.S. equity market, one factor has emerged as pivotal in determining whether a stock is likely to rise amid growing concerns over trade policy: how much the U.S. company focuses on the U.S.
On June 3, Johnson & Johnson’s (JNJ) pharma subsidiary, Jannsen, released data from a Phase 2 study of erdafitinib for the treatment of patients with metastatic or unresectable urothelial carcinoma (or mUC). Johnson & Johnson presented the study results at the 2018 ASCO (American Society of Clinical Oncology) Annual Meeting, along with results for some of its other oncology drug trials, as shown in the diagram below. Jannsen’s erdafitinib, a once-daily oral pan-FGFR (fibroblast growth factor receptor) inhibitor, was designated a breakthrough therapy by the FDA in March.
On June 6, Johnson & Johnson (JNJ) announced it had received a $2.8 billion offer from Fortive (FTV) to sell its ASP (Advanced Sterilization Products) business, part of its subsidiary, Ethicon. Ethicon’s ASP business, a market leader in infection prevention solutions, generated sales of $775 million in fiscal 2017. Johnson & Johnson has 120 days to decide on the offer.
On June 12, Johnson & Johnson (JNJ) announced it had accepted a $2.1 billion offer for the sale of its LifeScan business, which manufactures blood glucose monitoring devices and OneTouch products, from private equity company Platinum Equity. On June 12, JNJ stock fell ~0.42% following the deal announcement.
Johnson & Johnson (JNJ), one of the world’s largest healthcare companies, has a diversified business spanning its consumer, medical device, and pharmaceutical segments. The company reported sales of $20 billion in Q1 2018 and adjusted EPS of $2.06. Let’s look at Johnson & Johnson’s valuation metrics.
Johnson & Johnson (JNJ) closed June 18 at $121.30 per share. The stock reached a 52-week low of $118.60 on May 29 as the company scrapped a Phase 1b/2 trial for its drug, Darzalex, for the treatment of advanced or metastatic non-small cell lung cancer patients, in combination with Roche’s (RHHBY) Tecentriq. Since then, the stock has risen ~1.6%.
Johnson & Johnson (JNJ) is one of the biggest healthcare players in the world. However, it has been impacted by growing competition and pricing pressure in the industry in recent years and has revised its strategy. The company has witnessed recuperating sales in its medical devices business along with improving dynamics in its consumer business, which has encountered some litigation recently. The company’s pharmaceuticals business has performed steadily, with key trial data being announced. Let’s look at analysts’ recommendations for JNJ stock.
Allergan (AGN), a leading specialty pharmaceutical company, is focused on developing, manufacturing, and commercializing pharmaceutical and biologic products.
Teva’s (TEVA) much-awaited migraine drug, Fremanezumab, is in late-stage trials for the treatment of cluster headaches. The company provided an update regarding its Enforce Phase III clinical development program for the treatment of cluster headaches on June 15.
Purdue Pharma LP, Johnson & Johnson and other opioid makers faced one of the first extensive review of their legal defenses to state claims that they violated consumer-protection laws and created a public nuisance with the sale of the pain killers. New York state court Judge Jerry Garguilo on Monday rejected the pharma companies’ requests for the lawsuits be thrown out on a myriad of grounds, concluding lawyers for eight counties could move forward with their claims. While the ruling is based solely on New York law, it could provide a roadmap for other judges around the U.S. weighing whether states and local governments can proceed with claims that Purdue and other opioid makers understated the risks of prescription opioids and overstated their benefits.
Verizon was the only DJIA member trading significantly in the green on Tuesday. Deutsche Bank upgraded the wireless maker, saying shares were cheap.
Jim Cramer proposes starting a new exchange-traded fund with the stocks that scare investors most when trade tensions run high.
Swiss biotech Idorsia, spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson, will seek fresh funding in 2019 to support late-stage trials of drugs getting underway, its CEO told Reuters. French founders Jean-Paul Clozel and his wife, Martine Clozel, sold Actelion for $30 billion last year, but only after extracting rights to 11 prized drugs in development, including an insomnia medicine nicknamed DORA. With 650 employees, Jean-Paul Clozel expects to burn through Idorsia's cash in about two years, before his drug hopefuls generate revenue - typical of the biotech industry where the risk of pipeline failures is ever-present but the rewards of striking paydirt, as was the case with Actelion, can be vast.
Several big pharma companies are about to lose patent exclusivity for blockbuster drugs. Should investors be worried?
Morningstar’s annual investment conference in Chicago last week was noticeably different than in years past. The 30th iteration focused less on stocks, funds, and other investments, and instead emphasized technology and tools to analyze them. The three-day gathering also served up big-picture thinking from luminaries such as veteran investor and environmental evangelist Jeremy Grantham, and Nobel Prize–winning behavioral psychologist Danny Kahneman.
Glaxo's (GSK) two late-stage studies testing its two-drug HIV regimen of dolutegravir (Tivicay) and lamivudine showed non-inferiority to a standard three-drug regimen
Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health
In this article I am going to calculate the intrinsic value of Johnson & Johnson (NYSE:JNJ) using the discounted cash flows (DCF) model. Anyone interested in learning a bit moreRead More...